Brief: DSS Announces Licensing Of Impact Biomedical’s Linebacker Portfolio To Prophase Labs
21/07/2022 22:16
July 21 (Reuters) - DSS Inc DSS.A :
* DSS ANNOUNCES LICENSING OF IMPACT BIOMEDICAL’S LINEBACKER
PORTFOLIO TO PROPHASE LABS
Source text for Eikon: ID:nGNX4H6VmB
Further company coverage: DSS.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DSS
See all newsBrief: Dss Withdraws S-1 Registration Statement With SEC
Brief: Dss Reports Going Concern Audit Opinion In 2025 10-K Filing
Brief: Dss Inc Actively Evaluating Acquisition Opportunities Within Folding Carton Space
Brief: Dss, Inc. Announces Pricing Of $1.0 Million Underwritten Public Offering
Brief: DSS’s Subsidiary, Impact Biomedical, Announces Strategic Merger